Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Complete | ||
Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Lenvima | Lenvatinib | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (+bortezomib+dex) | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete |